Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (NEUGR-002)
A Randomized Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel)
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
A PHASE2/PHASE3 clinical study on Chemotherapy-induced Neutropenia, this trial is completed. The trial is conducted by Teva Branded Pharmaceutical Products R&D, Inc. and has accumulated 11 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Mar 2023 — May 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2023 — Mar 2023 [monthly]
Completed PHASE2_PHASE3
▶ Show 6 earlier versions
-
Apr 2022 — Jan 2023 [monthly]
Completed PHASE2_PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.